In layman’s terms, exosomes are extracellular vesicles, crucial in cell–to-cell communication which are being explored as a means of drug delivery. Also, the small vesicles that are created when stem cells are multiplied can target and help repair damaged cells.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees.
READ: InnoCan Pharma inks deal securing CBD for its coronavirus treatment collaboration with Tel Aviv University and other R&D projects
Recipharm unites more than 30 facilities across 10 different countries offering a range of services, mainly in two different operating areas -- pharmaceutical development services and manufacturing service.
InnoCan said Recipharm offers a wide range of GMP-compliant services ranging from manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices.
"Working closely with the exceptional Recipharm team will allow InnoCan Pharma to devote efforts with the exosome technology production/loading technology while the work on the cannabinoids themselves will be done at Recipharm," InnoCan CEO Iris Bincovich said in a statement.
Potential for different formulations
Dr Sylvia Kachalsky, site manager for Recipharm in Israel, said the project has the potential to be applied to a large spectrum of different indications.
“The idea of loading Exosomes with Cannabinoids may open a wide window to different formulations, using the Exosome as a 'targeted missile' leading the chosen Cannabinoid to its target," she added.
Professor Daniel Offen, who is leading InnoCan’s research, said the project will look to produce exosomes with CBD, adding that “the development of the CLX- CBD loaded Exosome is very challenging but holding huge potential.”
Israel-based InnoCan has previously stated that the exosomes could be used as treatments for coronavirus (COVID-19) and central nervous system disorders.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham